

1 **TITLE. COVID-19: age, Interleukin-6, C-Reactive Protein and lymphocytes as key clues from a multicentre**
2 **retrospective study in Spain.**

3 **AUTHORS.**

4 Aurora Jurado^{1,2}, María C. Martín^{1,3}, Cristina Abad-Molina⁴, Antonio Orduña⁴, Alba Martínez⁵, Esther Ocaña⁵, Oscar
5 Yarce², Ana M. Navas², Antonio Trujillo², Luis Fernández⁶, Esther Vergara⁶, Beatriz Rodríguez⁷, Bibiana Quirant⁸,
6 Eva Martínez-Cáceres⁸, Manuel Hernández⁹, Janire Perurena-Prieto⁹, Juana Gil¹⁰, Sergi Cantenys¹⁰, Gema González-
7 Martínez¹¹, María T. Martínez-Saavedra¹¹, Ricardo Rojo¹², Francisco M. Marco¹³, Sergio Mora¹³, Jesús Ontañón¹⁴,
8 Marcos López-Hoyos¹⁵, Gonzalo Ocejo-Vinyals¹⁵, Josefa Melero¹⁶, Marta Aguilar¹⁶, Delia Almeida¹⁷, Silvia Medina¹⁷,
9 María C. Vegas¹⁸, Yesenia Jiménez¹⁸, Álvaro Prada¹⁹, David Monzón¹⁹, Francisco Boix²⁰, Vanesa Cunill²¹, Juan
10 Molina²

11 ¹These authors contributed equally to this manuscript.

12 **Affiliations.**

13 ²Department of Immunology and Allergology. Hospital Universitario Reina Sofía-Instituto de Investigación
14 Biomédica de Córdoba (IMIBIC), Córdoba, Spain.

15 ³Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain

16 ⁴Department of Microbiology and Immunology. Hospital Clínico Universitario, Valladolid, Spain

17 ⁵Laboratory Unit. Complejo Hospitalario, Jaén, Spain

18 ⁶Laboratoy of Immunology and Genetics. Hospital San Pedro de Alcántara, Cáceres, Spain

19 ⁷Laboratory Unit. Hospital Juan Ramón Jiménez, Huelva, Spain

20 ⁸Department of Immunology. Hospital Germans Trias i Pujols, Barcelona, Spain

21 ⁹Department of Immunology. Hospital Universitario Vall d'Hebron, Barcelona, Spain

22 ¹⁰Department of Immunology. Hospital General Universitario e Instituto de Investigación Sanitaria “Gregorio
23 Marañón”, Madrid, Spain

24 ¹¹Unit of Immunology. Hospital Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, Spain

25 ¹²Department of Immunology. Complejo Hospitalario, La Coruña, Spain

26 ¹³Laboratory Unit. Hospital General, Alicante, Spain

27 ¹⁴Laboratory Unit. Hospital General Universitario, Albacete, Spain

28 ¹⁵Department of Immunology. Hospital Universitario Marqués de Valdecilla, Santander, Spain

29 ¹⁶Department of Immunology. Hospital Infanta Cristina, Badajoz, Spain

30 ¹⁷Laboratory Unit. Complejo Hospitalario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain

31 ¹⁸Department of Immunology. Fundación Jiménez Díaz, Madrid, Spain.

32 ¹⁹Department of Immunology. Hospital de Donostia, San Sebastián, Spain.

33 ²⁰Department of Immunology. Hospital Clínico Universitario, Salamanca, Spain.

34 ²¹Department of Immunology. Hospital Universitario Son Espases, Palma de Mallorca, Spain .

35 **Author for correspondence:** Dra M Carmen Martín. Centro de Hemoterapia y Hemodonación de Castilla y León.

36 Paseo de Filipinos s/n. 47007 Valladolid (Spain); email: cmartinalo@saludcastillayleon.es. Tf.: +34 983 41 88 23 ext

37 89673 Mobile +34 686 24 73 31

38

39 **ABSTRACT**

40 **Background.** SARS-CoV-2 infection has widely spread to the hugest public health challenge to date, COVID-19
41 pandemic. Different fatality rates among countries are probably due to non-standardized records being carried out
42 by local health authorities. Spanish case-fatality rate is 11.94%, far higher to those reported in Asia or by other
43 European countries. A multicenter retrospective study was performed of demographic, clinical, laboratory and
44 immunological features of 574 Spanish COVID-19 hospitalized patients and their outcomes. The use of use of
45 renin-angiotensin system blockers was also analyzed as a risk factor.

46 **Results.** In this study, 27.7% of cases presented a mild course, 42% a moderate one and for 30.3% of cases, the
47 course was severe. Ages ranged from 18 to 98 (average 63.2). Fifty eight percent (58.9%) of patients were male.
48 Interleukin 6 was higher as severity increased. On the other hand, CD8 lymphocyte count was significantly lower as
49 severity grew and subpopulations CD4, CD8, CD19 and NK showed concordant lowering trends. Severity-related
50 natural killer percent descents were evidenced just within aged cases. A significant severity-related decrease of
51 CD4 lymphocytes was found in males. The use of renin-angiotensin system blockers was associated with moderate
52 or mild disease courses.

53 **Conclusions.** Age and age-related comorbidities, such as dyslipidaemia, hypertension or diabetes, determined
54 more frequent severe forms of the disease in this study than in previous literature cohorts. Our cases are older
55 than those so far reported and clinical course of the disease is found to be impaired by age. Immunosenescence
56 might be therefore a suitable explanation for immune system effectors severity-related hampering. Adaptive
57 immunity would go exhausted and a huge ineffective and almost deleterious innate response would account for
58 COVID-19 severity. Renin-angiotensin system blockers treatment in hypertensive patients has a protective effect as
59 regarding COVID-19 severity.

60 **Keywords:** severe acute respiratory syndrome coronavirus 2, COVID-19, immunosenescence, immunity, renin-
61 angiotensin system, ACE2, interleukin-6, C-reactive protein, lymphocytes.

62

63 BACKGROUND

64 SARS-CoV-2 infection has become worldwide widespread. Never before did we experience a health emergency like
65 this. At the time of writing, four months after the first diagnosed case [1] the virus has infected 4 690 287 people,
66 with an overall case-fatality rate of 6.69% [2] far exceeding the 1% reported outside the epicentre by early studies
67 [3]. It can be traced back to the end of February, when the pandemic started to rapidly expand, hitting the hardest
68 some European countries, such as Spain, with case-fatality rates around 11.94%. So far, we lack an explanation to
69 this particular behaviour, although it could be due either to different local approaches for records and statistics of
70 infected patients within countries or to demographical features. Absolute mortality rates are far higher in Spain
71 than those reported in Asia or other European countries [4].

72 It was by 2002, in the SARS-CoV epidemic, when a coronavirus was for the first time revealed to be highly
73 pathogenic. Coronaviruses were until then considered to cause only mild infections, mainly in
74 immunocompromised people [5]. Compared with SARS-CoV, SARS-CoV-2 has shown a much higher infectivity with
75 a doubling time of 2.3-3.3 days, and a basic reproductive number [R_0] of 5.7 [6]. SARS-CoV-2 can be considered
76 specially challenging due to several intrinsic and extrinsic characteristics. It has a highly variable prevalence and
77 outcomes within countries depending on age, weather and social habits.

78 Angiotensin-converting enzyme 2 (ACE2) is the receptor for SARS-CoV-2 and plays a key role in human infection
79 [7]. ACE2 has two isoforms; a large one anchored to the cell membrane [8] and a small soluble isoform lacking
80 anchorage to the membrane and circulating in low amounts in peripheral blood [9]. Hence, it has been suggested
81 that the use of drugs that increase the expression of ACE2, such as angiotensin converting enzyme inhibitors and
82 angiotensin II receptor blockers, could enhance infection [10]. On the other hand, increasing soluble ACE2 may be
83 a therapeutic tool to block the virus [11]. The habit of smoking can as well rise ACE2 expression and might be
84 therefore a risk factor for SARS CoV2 infection [12].

85 Both innate and adaptive responses are involved in SARS-CoV-2 fighting [13]. An accurate immune response is
86 essential for infection resolution. In SARS-CoV-2 infection, an aberrant immune response itself might be the key to

87 understand the immunopathogenesis. It looks as if the progression to severe COVID-19 were associated with a
88 poor adaptive immune response [14] and with an exacerbation of the innate immune response, with an increase in
89 plasma levels of cytokines and pro-inflammatory chemokines [15].

90 Understanding the pathogenesis of the virus as well as identifying risk or severity factors for COVID-19, are key
91 points for identifying disease evolution biomarkers and taking immediate preventive actions.

92 The aim of this study was therefore to obtain, within the shortest possible time, a reliable snapshot of the
93 demographic and clinical characteristics of COVID-19 patients admitted to Spanish hospitals along the first month
94 of the pandemic and to reveal risk factors regarding outcome severity. This knowledge would help manage both
95 clinical and public health decisions.

96 **RESULTS**

97 A total of 574 SARS-CoV-2 infected inpatients from 19 Spanish Hospitals were included. Twenty-seven percent
98 (27.7%) of cases presented a mild course, 42.0% a moderate one and 30.3% a severe one. By data collection
99 deadline, 266 patients had been discharged and 84 had died. Descriptive baseline characteristics of population
100 (valid n, frequencies, percentages, mean, median, standard deviation and interquartile range) are shown in Table
101 1. Categorical variables stratified by severity are shown in Table 2.

102 Fifty nine percent (59.4%) of cases were male. Ages in our cohort ranged from 18 to 98 years, with a mean of 63.2
103 years (SD 16.4). Concerning comorbidities, 52.4% were hypertensive, 63.2% of them were treated with blockers of
104 renin-angiotensin system (RABs); twenty-eight percent 28.9% had dyslipidaemia and 23.8% suffered diabetes.
105 Immunodeficiency diseases were most often secondary to other processes, such as a transplantation or
106 chemotherapy treatment, these cases accounted for 8.2% (n=39) as seen in Table 1.

107 Both moderate and severe courses were found to be significantly associated with older age ($p=0.014$), male
108 gender ($p<0.001$), dyslipidaemia ($p=0.006$), hypertension ($p=0.04$) and diabetes ($p=0.007$). Severe cases over the
109 age of 75 accounted for a 36.1%. The use of renin-angiotensin system blockers by hypertensive patients was
110 associated, ($p=0.031$), with mild or moderate outcomes (Table 2).

111 Once at hospital, 84.8% of inpatients received antibiotics; the most commonly prescribed ones were azithromycin
112 combinations (71.3%); those treated with antimalarial drugs accounted for 72.6% and 66% received antivirals,
113 being litonavir/ritonavir the most widely used. Around one half, 51% of cases, received combined therapy with
114 antibiotics, antimalarials and antivirals (commonly named triple therapy). Immunosuppressant drugs were used in
115 18.7% cases. Anti-cytokine therapy was used in 8.6%, mostly anti-IL-6R (Tocilizumab), and 17.7% were treated with
116 interferons α or β (Table 1).

117 On admission, means of laboratory parameters, IL-6, CRP, ferritin, D-dimer, LDH, leukocyte and neutrophil counts,
118 were above reference ranges, opposite to lymphocyte subsets' counts (Table 1). Higher severity was significantly
119 associated with higher IL-6, CRP, ferritin, D-dimer, LDH, leukocyte and neutrophil counts, but lower lymphocyte
120 percent (Supplementary Table 1). Mean values of lymphocyte subpopulations percentages (n=54) were within
121 normality ranges. CD8 Lymphocyte count was found to be significantly higher in mild cases, a similar trend was
122 found for CD4, CD8, CD19 and NK percentages. IgG and IgM values were as well inversely related to severity
123 (Supplementary Table 1).

124 At discharge, IL-6, ferritin, D-dimer, LDH, leukocyte and neutrophil counts remained significantly higher within
125 severe cases as compared to mild or moderate ones. Lymphocyte count turned significantly higher in severe cases
126 as compared to mild or moderate (Supplementary Table 1). CRP values at discharge were nearly in range
127 regardless of severity. Notwithstanding, when comparing laboratory data at discharge with those on admission, an
128 overall return to reference ranges of most parameters was observed, with lower mean values of CRP, LDH and IL-6
129 and higher mean values of percentage and absolute lymphocyte count. D-dimer and ferritin still showed values
130 above reference ranges with no significant differences as compared to these upon arrival.

131 Most differences among groups were kept as regarding aging (Figure 1). It could be evidenced that lymphopenia
132 and increased IL-6 remained significant regarding severity in all age groups but in patients under 30. CD8
133 population differences (both in absolute count and percent) were significant only as regarding 45-60 group (the
134 largest one). Lymphocyte count decrease –that was seen as a global change- was only evidenced for 30-45 and 45-
135 60 age ranges. NK % was higher in milder cases within older individuals (60-75 and <75). Severity-related decreases
136 of CD4 (p 0.007) and CD8 (p 0.008) lymphocytes were evidenced just in males (Figure 2). Hypertension,

137 dyslipidaemia and diabetes grew more frequent with age ($p < 0.001$, Table 3). These four risk factors showed strong
138 interferences (Figure 3). Nevertheless, a predictive model couldn't be proposed due to frequent missing values.

139 **DISCUSSION**

140 COVID-19 pandemic has become particularly virulent in Mediterranean countries such as Spain, both in terms of
141 number of affected people and fatalities. This is the first report on Spanish COVID-19 inpatients; our aim was to
142 outline disease's demographic characteristics, risk factors and laboratory parameters, in relationship to disease
143 severity.

144 In our series, 27.7% of patients showed a mild course, 42% a moderate course and 30.3% a severe one. Several
145 works analyse severity in COVID-19 inpatients, almost all from Chinese hospitals. Those, including two multicentre
146 studies, show a presentation in which the most severe cases ranged from 16% to 26% [16-19], except for the study
147 of Zhou et al. [20], where critical cases reached 28%.

148 It has been reported elsewhere in papers on risk factors affecting the course of the disease, that older patients or
149 those with at least one previous comorbidity had a worse prognosis [16,19-21]. There are, however, remarkable
150 differences within these studies. Spanish inpatients were much older than those in previously reported cohorts,
151 with an average age of 63.2 years. Previous literature, including one meta-analysis and two multicentre studies,
152 reports ages ranging from 36 to 58 [16-20,22-24]. On the other hand, Grasselli et al. [25], in a multicentre Italian
153 study focusing on patients admitted to the ICU, reports an average age of 63, similar to that in our cohort.

154 In SARS-CoV-2 infection, the number of paediatric patients is lower with milder symptoms and better prognosis
155 [26] as compared to adults. This fact highlights the possible effect of immunosenescence on the course of the
156 disease [27]. Immunosenescence refers to the age-associated decline of the immune system, affecting both innate
157 and adaptive immunity. Aging is associated with a greater susceptibility to infections [28]. People over 60
158 represent 11% of the worldwide population and they are expected to reach 22% by 2050 [28]. In Spain, to date,
159 19.4% of the population is over 65 [29].

160 Possibly due to ageing, it can be observed that frequencies for comorbidities such as hypertension or diabetes,
161 were higher in our series than those reported in previous studies [16, 17, 19-24, 30] and higher than the diabetes
162 prevalence among Spanish adult population (23.5% vs 13.8%) [31]. Notwithstanding, the prevalence of

163 hypertension mirrored those of the general adult Spanish population (overall, 42.6%; people over 60, 75.4%) [32].
164 Not only SARSCoV2, but most human coronaviruses, strike harder the elderly and those with underlying
165 comorbidities [33], probably as a consequence of a worse immune response control.

166 As in previous studies, patients were more frequently males [19, 20, 22, 24]. This fact is even more noteworthy,
167 considering that the percentage of men in the Spanish population over 50 years of age is 41.7% [29], under 59.4%
168 in our COVID-19 cohort. In addition to remark, male gender was associated with severity. There is an Italian report
169 of patients admitted to ICU, with a percentage of males reaching 80% [25] that would go in the same line of our
170 observed gender effect on severity.

171 Concerning laboratory parameters, our findings were comparable to those reported in previous studies, with
172 increases of acute phase reactants (CRP, D-dimer, LDH, ferritin) growing with severity and decreasing when the
173 evolution of patients was favourable [19, 20, 22, 30]. Particularly striking was the evolution of the CRP, which was
174 almost within reference range at discharge.

175 Several publications have focused on immunological markers in COVID-19 [19, 20, 30]. The most extensive one is
176 the work of Diao et al. [14], which analyses the secretory profile of inflammatory cytokines, lymphocyte
177 populations and their relationship to disease severity in 499 patients. The authors found an increase in pro-
178 inflammatory cytokines inversely correlated to T-lymphocyte populations. This immune profile was as well related
179 to the severity of the disease. CD4, CD8 and IL-6 are reported to covariate at least in mild cases [34] and behave
180 like in our series, where an increase in IL-6 and a decrease in both total lymphocytes and lymphocyte populations
181 could be seen. Once again, these changes were greater, the more severe the condition. However, in our study
182 almost any lymphocyte population: CD4, CD8, CD19 and NK were below reference ranges upon arrival and were
183 even more markedly decreased in severe cases, in spite of differences being only significant for CD8 population as
184 regarding overall data.

185 Since the seminal publication of Lei Fang et al. on the possible involvement of renin-angiotensin system blockers in
186 SARS-CoV-2 infection [10] just two months ago, there has been much ado about. No sooner had the scientific
187 community realized its foreseeable impact, they began to take sides with articles both for and against the
188 hypothesis [35-38]. ACE2 molecules are the pathway used by SARS-CoV-2 to enter the cell [39]. RASBs indirectly

189 increase the expression and secretion to the extracellular medium of ACE2 in various cell types, including airway
190 alveolar epithelial cells [35]. Therefore, RASBs use might enhance either the entry of the virus or its blockade
191 preventing it from infecting the cell [36]. Additionally, the expression of ACE2 is associated with positive effects on
192 lung homeostasis, those could be beneficial for tissue recovery from the damage caused by SARS-CoV-2 infection
193 [11, 36]. ACE2 expression is reported to be related to age and sex. It would be highest in children and young
194 women, decreasing with ageing, and would be lowered due to chronic disease comorbidities, including diabetes
195 and hypertension [40]. ACE2 will inversely correlate severity and poor outcomes. Most literature for or against the
196 role of the use of RASB consist mainly of theoretical positioning based on the knowledge of these drugs'
197 physiological actions. There are limited original studies analysing RASB intake effect on COVID-19. Tedeschi et al.
198 [41], in order to elucidate whether RASB treatment had an impact on COVID-19 mortality, analysed 311
199 hypertensive patients hospitalized in 10 Italian centres. At multivariate Cox regression analysis of intra-hospital
200 mortality, the use of RASB was not found to be associated with outcome. Moreover, Chen et al. [30] reported 113
201 hypertensive patients, 33 (29.2%) that were on RASB treatment, 87.9% of whom had a moderate course of the
202 disease and 12.2% a severe or critical course. In our series, out of 290 hypertensive patients, 190 (67.4%) were
203 taking RASB; a feature comparable to the intake of these compounds by the Spanish hypertensive population [32].
204 Those patients treated with RASB drugs had a milder course of the disease (OR 0.61, 95% CI [0.37-0.99]; p 0.03).
205 The present study has two major limitations. The first one is derived from its retrospective design. As we are
206 reporting on the very first cases of the disease in Spain, several immunological parameters of interest were not
207 systematically tested. The other constraint is the short follow-up period of patients, which limits the possibility to
208 have a full track of those who were still in hospital by data collection deadline. Consequently, the relationship
209 among other variables such as treatment or other outcomes such as death, have not been here analysed.

210 **CONCLUSIONS**

211 To summarize, our patients are older and developed more often severe COVID-19 condition than the previously
212 reported cohorts. Age has emerged as a crucial factor in our series. Age is as well one of the major determinants
213 for all other COVID-19 risk comorbidities, such as hypertension, diabetes, or dyslipidaemia. Immunosenescence
214 might be a suitable explanation for the immune overwhelming observed in the severest cases. Regarding not only

215 our series but other worldwide ones, the effectors of the immune system are hampered as severity increases.
216 Adaptive immunity has been suggested to be disabled by SARS CoV2, that feature is so named exhausted
217 immunity. This exhaustion would be coupled with a huge ineffective and almost deleterious innate response.
218 Further studies specifically aimed at assessing the immune system status in SARS-CoV-2 infected patients should
219 be carried out to support immunosenescence hypothesis. Nevertheless, it is clear from data that elderly are at
220 special COVID-19 risk and should be therefore paid special attention by public health services.

221 **METHODS**

222 **Aim, design and setting of the study.**

223 The aim of this study was to obtain, within the shortest possible time, a reliable snapshot of the demographic and
224 clinical characteristics of COVID-19 patients admitted to Spanish hospitals along the first month of the pandemic
225 and to reveal risk factors regarding severity. So, a retrospective observational multicentre analysis was performed
226 in 19 Spanish hospitals.

227 **Participants.**

228 The study population comprised the first consecutive set of SARS-CoV-2 infected inpatients, microbiologically
229 confirmed by positive PCR test, during the second half of March 2020. Cases were tracked for a three-week follow-
230 up period from admission to discharge. A minimum sample size of 20 patients was considered for every hospital. In
231 some cases, this minimum was exceeded. A total of 642 medical records of individuals over 18 years old, from 19
232 Spanish hospitals were initially reviewed. After data quality assessment, 574 patients were finally included in the
233 analyses. Participants were stratified into three severity groups before analysis according to the following clinical
234 criteria:

- 235 • Mild: individuals whose clinical symptoms were mild with no abnormal radiological findings
- 236 • Moderate: cases with confirmed pneumonia that was not considered severe

- 237 • Severe: when at least one of the following criteria was met: acute respiratory distress, shock, admission to
238 the intensive care unit (ICU), or the process was so considered by the physician in charge. Any “exitus”
239 was as well classified as severe.

240 **Data collection**

241 All data were extracted from electronic medical records. The collection form included demographic,
242 epidemiological and clinical data: age, sex, history of diabetes mellitus (DM), dyslipidaemia, hypertension (HTA),
243 renin-angiotensin system blocker intake (RASB), COVID-19 severity, time from onset to diagnosis, laboratory data
244 on admission and discharge, treatment, and outcome. At the end of data collection, some patients were still in
245 hospital. In these cases, laboratory data at discharge could not be provided.

246 **Laboratory data**

247 Major laboratory markers were extracted from medical records at admission and discharge. Routine blood
248 examinations included leukocyte, neutrophil and lymphocyte count ($\text{cells} \times 10^3/\mu\text{L}$) and lymphocyte percentage.
249 Serum biochemical tests recorded were ferritin ($\mu\text{g/L}$), lactate dehydrogenase (LDH, U/L), C- reactive protein (CRP)
250 and D-dimer ($\mu\text{g/L}$). Immunological tests recorded were interleukin-6 (IL-6, pg/mL), Lymphocyte population count
251 ($\text{cells} \times 10^3/\mu\text{L}$) and percentage by flow cytometry, immunoglobulins IgG, IgA and IgM (mg/dL).

252 **Statistical analysis**

253 Demographic and clinical characteristics of patients were expressed as their mean and standard deviation (SD);
254 when not adjusting to a normal distribution, median was used to represent non-parametrical data for continuous
255 variables and frequency distributions are reported for categorical variables. Age was analysed both, as continuous
256 and categorical variable; in the latter case was recoded into 5 groups: <30, 30-45, 45-60, 60-75, >75

257 Kolmogorov-Smirnov test was performed on each continuous variable to contrast normality. To analyse the overall
258 differences between the three groups: mild, moderate, and severe type, ANOVA was tested on variables with
259 normal distribution and $n > 30$ (age, % and CD4 lymphocyte count, % of CD8 lymphocytes, % of CD19 lymphocytes
260 and % of NK). To analyse severity relationships of non-parametric or $n < 30$ variables, a Kruskal-Wallis test was used.
261 A t-test was performed to contrast damage-free discharge for normal variables and a Mann Whitney test for non-

262 parametric measures. To contrast the Ho of independence within categorical variables, Pearson's Chi-square and
263 Fisher's exact test were used. To compare values of recurrent parameters measured in a same individual at
264 admission and discharge, Wilcoxon test for paired data was performed.

265 **Abbreviations.**

266 Angiotensin-converting enzyme 2 (ACE2); renin-angiotensin system blockers (RASB); lactate dehydrogenase (LDH);
267 C- reactive protein (CRP); interleukin-6 (IL-6); immunoglobulin G (IgG); immunoglobulin A (IgA); immunoglobulin M
268 (IgM); polymerase chain reaction (PCR); standard deviation (SD); interquartile range (IQR); Natural Killers (NK).

269 **DECLARATIONS**

270 **Ethics approval**

271 This study was conducted according with national regulations, institutional policies and in the tenets of the
272 Helsinki Declaration. This study was approved, with the Valladolid Health Area Drug Research Ethics Committee
273 acting as the main committee, in a meeting held on March 31, 2020 and with the reference number "PI 20-172-
274 NO-HCU". Moreover, it was approved by each of the local institutional Ethics Committee of the 19 hospitals
275 involved.

276 **Availability of data and materials**

277 Data collected for the study, including fully anonymized participant data, are available to others. Data available
278 include fully anonymized participant data and data dictionary. Related documents are available from the date of
279 publications henceforth: study protocol, statistical analysis, and approval of Ethical Board. These documents are
280 available from the date of publications henceforth at email address cmartinalo@saludcastillayleon.es or
281 aurora.jurado.ssapa@juntadeandalucia.es

282 Data will be shared after approval of proposals by the Valladolid Este Ethical Committee.

283 **Competing interests**

284 Authors stated no conflicts of interest.

285 **Funding**

286 This work has been carried out without funding.

287 **Authors' contributions**

288 AJ and MCM conceived the idea for this study, designed the protocol, analysed the data and drafted the
289 manuscript. The remaining authors collected the data and assessed for data quality. All authors provided critical
290 revisions and approved the final version of the manuscript.

291 **Acknowledgements**

292 The authors thank to all caregivers who indirectly contributed to this multicentre study. They also thank Spanish
293 Immunology Society for its support and endorsement

294 **References**

- 295 1. Du Toit A. Outbreak of a novel coronavirus. *Nat Rev Microbiol.* 2020;18(3):123.
- 296 2. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins
297 University (JHU). Available at: <https://coronavirus.jhu.edu/map.html>
- 298 3. Kenji Mizumoto K, Gerardo Chowell G. Estimating Risk for Death From 2019 Novel Coronavirus Disease,
299 China, January-February 2020. *Emerg Infect Dis.* 2020;26(6). Available at: <https://doi.org/10.3201/eid2606.200233>.
- 300 4. Oksanen A, Kaakinen M, Latikka R, Savolainen I, Savela N, Koivula A. Regulation and trust: 3-month follow-
301 up study on COVID-19 mortality in 25 european countries. *JMIR Public Health Surveill.* 2020;6(2) e19218.
- 302 5. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol.* 2019;17(3):181-
303 192
- 304 6. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High contagiousness and rapid spread of
305 severe acute respiratory syndrome coronavirus 2. *Emerg Infect Dis.* 2020;26(7). Available at:
306 <https://doi.org/10.3201/eid2607.200282>
- 307

- 308 7. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2
309 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. *Front*
310 *Med.* 2020;1-8. Available at: [https://doi: 10.1007/s11684-020-0754-0](https://doi.org/10.1007/s11684-020-0754-0)
- 311 8. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H. 2020. Genomic Characterisation and epidemiology of 2019 novel
312 coronavirus: implications for virus origins and receptor binding. *Lancet.* 395(10224):565-574.
- 313 9. Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K. et al. Targeting and degradation of
314 angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent
315 hypertension. *Hypertension.* 2010;55(1):90-8.
- 316 10. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for
317 COVID-19 infection? *Lancet Respir Med.* 2020;8(4): e21.
- 318 11. Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for
319 coronavirus infection therapy? *Clin Sci [Lond].* 2020;134(5):543-545.
- 320 12. Cai G, Bossé Y, Xiao F, Kheradmand F, Amos CI. Tobacco Smoking Increases the Lung Gene Expression of
321 ACE2, the Receptor of SARS-CoV-2. *Am J Respir Crit Care Med.* 2020. Available at: [https://doi:](https://doi.org/10.1164/rccm.202003-0693LE)
322 [10.1164/rccm.202003-0693LE](https://doi.org/10.1164/rccm.202003-0693LE)
- 323 13. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection: the perspectives on immune
324 responses. *Cell Death Differ.* 2020;27(5):1451-1454
- 325 14. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L et al. Reduction and Functional Exhaustion of T Cells in
326 Patients with Coronavirus Disease 2019 (COVID-19). *medRxiv preprint*, 2020. Available at:
327 <https://doi.org/10.1101/2020.02.18.20024364>
- 328 15. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of
329 cytokine storm and immunopathology. *Semin Immunopathol.* 2017;39(5):529-539
- 330 16. Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus
331 disease 2019 [COVID-19] in Changsha. *Eur Rev Med Pharmacol Sci.* 2020;24(6):3404-3410.
- 332 17. Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y et al. Clinical characteristics and outcomes of
333 hospitalized patients with COVID-19 treated in Hubei [epicenter] and outside Hubei [non-epicenter]: A

- 334 Nationwide Analysis of China. *Eur Respir J*. 2020;2000562. Available at: <https://www.doi.org/10.1183/13993003.00562-2020>
335
- 336 18. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z. et al. Characteristics of COVID-19 infection in Beijing. *J Infect*.
337 2020;80[4]:401-406.
- 338 19. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J. COVID-19 with Different Severity: A Multi-center Study of Clinical
339 Features. *Am J Respir Crit Care Med*. 2020. Available at: [https://doi: 10.1164/rccm.202002-0445OC](https://doi.org/10.1164/rccm.202002-0445OC).
- 340 20. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients
341 with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*. 2020;28;395(10229):1054-1062.
- 342 21. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y. Dysregulation of immune response in patients with COVID-19
343 in Wuhan, China. *Clin Infect Dis*. 2020. Available at: <https://doi.org/10.1093/cid/ciaa248>
- 344 22. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB. COVID-19 patients' clinical characteristics,
345 discharge rate, and fatality rate of meta-analysis. *J Med Virol*. 2020. Available at: [https://doi:](https://doi.org/10.1002/jmv.25757)
346 [10.1002/jmv.25757](https://doi.org/10.1002/jmv.25757).
- 347 23. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S et al. Risk factors associated with acute respiratory distress
348 syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern*
349 *Med*. 2020;13. Available at: [https://doi: 10.1001/jamainternmed.2020.0994](https://doi.org/10.1001/jamainternmed.2020.0994)
- 350 24. Cao J, Tu WJ, Cheng W, Yu L, Liu YK, Hu X. Clinical features and short-term outcomes of 102 patients with
351 corona virus disease 2019 in Wuhan, China. *Clin Infect Dis*. 2020. Available at
352 <https://doi.org/10.1093/cid/ciaa243>
- 353 25. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A. Baseline characteristics and outcomes
354 of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA*. 2020;6.
355 Available at [https://doi: 10.1001/jama.2020.5394](https://doi.org/10.1001/jama.2020.5394).
- 356 26. J Cai J, Xu J, Lin D, Yang Z, Xu L, Qu Z et al. A Case Series of children with 2019 novel coronavirus infection:
357 clinical and epidemiological features. *Clin Infect Dis*. 2020;ciaa198. Available at:
358 <https://www.doi.org/10.1093/cid/ciaa198>

- 359 27. Koff WC, Williams MA. Covid-19 and Immunity in Aging Populations. A new research agenda. *N Engl J*
360 *Med.* 2020. Available at: <https://www.DOI:10.1056/NEJMp2006761>
- 361 28. Pera A, Campos C, López N, Hassouneh F, Alonso C, Tarazona R, et al. Immunosenescence: implications for
362 response to infection and vaccination in older people. *Maturitas.* 2015;82(1):50-5.
- 363 29. Instituto Nacional de Estadística. Ministerio de Economía y Hacienda. Gobierno de España. Available at:
364 <https://www.ine.es/jaxi/Tabla.htm?path=/t20/e245/p04/provi/l0/&file=0ccaa003.px&L=0>
- 365 30. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and
366 moderate coronavirus disease 2019. *J Clin Invest.* 2019;pii:137244. Available at: [https://www.doi:](https://www.doi:10.1172/JCI137244)
367 [10.1172/JCI137244](https://www.doi:10.1172/JCI137244).
- 368 31. Soriguer F, Valdes S, Rojo G. The Di@bet.es study: and now what? *Av Diabeto.* 2012;28(2):35-37
- 369 32. Menéndez E, Delgado E, Fernández-Vega F, Prieto MA, Bordiú E. Prevalence, diagnosis, treatment, and
370 control of hypertension in Spain. Results of the Di@bet.es Study. *Rev Esp Cardiol.* 2016;69(6)572–578
- 371 33. Felsenstein S, Herbert JA, Paul S, McNamara P, Hedrich CM. COVID-19: Immunology and treatment
372 options. *Clin Immunol.* 2020;215:108448. Available at: <https://doi.org/10.1016/j.clim.2020.108448>
- 373 34. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Relationships among lymphocyte subsets, cytokines, and the
374 pulmonary inflammation index in coronavirus [COVID-19] infected patients. *Br J Haematol.*
375 2020;189(3):428-437.
- 376 35. Rico-Mesa JS, White A, Anderson AS. Outcomes in patients with COVID-19 infection taking ACEI/ARB. *Curr*
377 *Cardiol Rep.* 2020;22(5):31.
- 378 36. Sommerstein R, Kochen MM, Messerli FH, Gräni C. Coronavirus disease 2019 [COVID-19]: Do angiotensin-
379 converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? *J Am Heart Assoc.*
380 2020;9(7):e016509.
- 381 37. Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an Association Between COVID-19
382 Mortality and the Renin-Angiotensin System—a Call for Epidemiologic Investigations. *Clin Infect Dis.*
383 2020;ciaa329. Available at: <https://doi:10.1093/cid/ciaa329>.

- 384 38. Sommerstein R. 2020. Re: Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for
385 fatal Covid-19. *BMJ*, 2020;368:m81. Available at: <https://www.bmj.com/content/368/bmj.m810/rr-2>
- 386 39. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z et al. Structural and functional Basis of SARS-CoV-2 entry
387 by using human ACE2. *Cell*. 2020;pii:S0092-8674[20]30338-X. Available at: [https://doi:](https://doi.org/10.1016/j.cell.2020.03.045)
388 [10.1016/j.cell.2020.03.045](https://doi.org/10.1016/j.cell.2020.03.045)
- 389 40. Ciaglia E, Vecchione C, Puca AA. COVID-19 Infection and Circulating ACE2 Levels: Protective Role in
390 Women and Children. *Front Pediatr*. 2020;8:206. doi: [10.3389/fped.2020.00206](https://doi.org/10.3389/fped.2020.00206).
- 391 41. Tedeschi S, Giannella M, Bartoletti M, Trapani F, Tadolini M, Borghi C, et al. Clinical impact of renin-
392 angiotensin system inhibitors on in-hospital mortality of patients with hypertension hospitalized for
393 COVID-19. *Clin Infect Dis*. 2020;ciaa492. Available at: <https://doi.org/10.1093/cid/ciaa492>

TABLES

Table 1. Baseline characteristics of the study population

Clinical and demographic characteristics	All patients n=574; (%)
Severity	
Mild	159 (27.7)
Moderate	241 (42)
Severe	174 (30.3)
Gender	
Male	341 (59.4)
Female	233 (40.6)
Hypertension	290 (52.4)
RASB ^a intake	
no	100 (32.6)
yes	190 (67.4)
Dyslipidaemia	157 (28.9)
Diabetes	129 (23.8)
Immunodeficiency (primary or secondary)	39 (8.2)
Antiviral therapy	378 (66.0)
Antimalarial therapy	416 (72.6)

Antibiotic therapy	487 (84.7)					
Immunosuppression therapy	106 (18.7)					
Anti-cytokine therapy	49 (8.6)					
Interferon therapy	101 (17.7)					
Triple therapy	293 (51.0)					
	Ref.v ^b	n	Mean	Median	SD ^c	IQR ^d
Age		574	63.2	64.0	16.4	52-76
laboratory data on admission						
IL-6 ^e (pg/mL)	<4.4	253	114.3	41.1	355.8	16.3-94.6
CRP ^f (mg/L)	<10	518	111.80	87.60	93.96	39-154.3
ferritin (ng/mL)	20-250	295	1112.71	793.00	1528.53	361-1417
D-dimer (ng/mL)	<500	455	1888.58	621.00	8222.87	400-1172
LDH ^g (U/L)	120-246	459	334.82	292.00	187.67	232-393
days from onset to admission		538	7.25	7.00	5.15	4-10
Leucocyte count (cells*10 ³ /μL)	4-12.4	562	7.60	6.40	5.62	4.89-9.03
Neutrophil count (cells*10 ³ /μL)	1.9-8	562	5.66	4.62	3.71	3.31-7.12
Lymphocyte count (cells*10 ³ /μL)	0.9-5	562	1.17	1.00	1.07	0.71-1.4
Lymphocyte %	19-48	562	18.28	16.00	11.41	9.7-23.5
CD3+CD4+ %	25-65	54	44.71	44.95	10.74	37-51.3
CD3+CD4+ count (cells*10 ³ /μL)	0.5-1.4	54	0.54	0.43	0.38	0.27-0.69
CD3+CD8+ %	12-40	54	23.36	24.15	9.82	15.6-30.5
CD4+CD8+ count (cells*10 ³ /μL)	0.25-1	54	0.28	0.20	0.22	0.12-0.36
CD19+ %	5-20	51	12.39	11.50	6.88	8-14.83
CD19+ count (cells*10 ³ /μL)	0.1-0.5	51	0.13	0.10	0.09	0.06-0.20
Natural Killer %	5-20	51	16.06	15.00	9.09	8-20.6

Natural Killer count (cells*10 ³ /μL)	0.5-5	51	0.17	0.14	0.12	0.08-0.20
Immunoglobulin G (mg/dL)	650-1600	19	961.6	933.0	131.3	885-1006
Immunoglobulin A (mg/dL)	40-350	19	230.9	223.0	72.3	178-248
Immunoglobulin M (mg/dL)	50-300	19	103.1	90.0	39.8	72-129
Laboratory data at discharge						
IL-6 (pg/mL)	<4.4	114	100.46	8.84	721.15	3.9-21.77
CRP (mg/L)	<10	286	30.75	13.72	45.52	5-37.7
ferritin (ng/mL)	20-250	197	819.80	633	865.41	290-1163
D- dimer (μg/L)	<500	256	3264.93	590.5	34427.29	366-1127
LDH (U/L)	120-246	257	272.76	234	312.86	195-280
days from admission to discharge		129	10.83	10	6.55	7-14
Leucocyte count (cells*10 ³ /μL)	4-12.4	309	7.22	6.38	3.39	4.96-8.28
Neutrophil count (cells*10 ³ /μL)	1.9-8	309	4.93	4.04	3.35	2.92-5.8
Lymphocyte count (cells*10 ³ /μL)	0.9-5	309	1.52	1.43	0.76	1-1.9
Lymphocyte %	19-48	309	23.77	24	11.77	14.8-31.6
CD3+CD4+ %	25-65	13	49.86	54	14.69	49-58.24
CD3+CD8+ %	12-40	13	19.88	20	10.42	10-29.27
CD19 %	5-20	13	16.67	10.86	21.12	7.9-15
Natural Killers %	5-20	13	11.64	11	5.70	9-15

Abbreviations: RASB^a, renin-angiotensin system blockers; Ref.v^b, reference values; SD^c, standard deviation; IQR^d, interquartile range; IL-6^e, interleukin-6; CRP^f, C-reactive protein; LDH^g, lactate dehydrogenase.

Table 2. Risk Factors by severity

	Mild	Moderate	Severe
Age (p=0.014)			
<30	9 (40.9)	9 (40.9)	4 (18.2)
30-45	26 (40.0)	23 (35.4)	16 (24.6)
45-60	41(26.8)	62 (40.5)	50 (32.7)
60-75	44 (33.3)	57 (43.2)	31 (23.5)
>75	39 (19.3)	90 (44.6)	73 (36.1)
Gender (p<0.001)			
Male	75 (22.0)	141 (41.3)	125 (36.7)
Female	69 (23.8)	129 (44.5)	92 (31.7)
Hypertension (p=0.04)			
No	88 (33.5)	105 (39.9)	70 (26.6)
Yes	69 (23.8)	129 (44.5)	92 (31.7)
RASB³ intake (p=0.031)			
No	19(17.1)	47 (42.3)	45 (40.5)
Yes	49(25.7)	86 (45.0)	56 (29.3)
Dyslipidaemia (p=0.006)			
No	127(32.8)	155 (40.1)	105 (27.1)
Yes	30(19.1)	74 (47.1)	53 (33.8)

Diabetes (p=0.007)

No 133 (32.1) 171 (41.3) 110 (26.6)

Yes 24 (18.6) 58 (45.0) 47 (36.4)

Immunodeficiency

No 281 (60.9) 373 (80.7) 270 (58.4)

Yes 8 (68.9) 20 (101.4) 11 (29.7)

Abbreviations: RASB^a, renin-angiotensin system blockers

Table 3. Influence of age and gender on comorbidities

		Age					Gender	
		<30	30-45	45-60	60-75	>75	Male	Female
		n(%)	n(%)	n(%)	n(%)	n(%)	n(%)	n(%)
Hypertension*	no	20(7.6)	53(20.2)	95(36.1)	52(19.8)	43(16.3)	149(56.7)	114(43.3)
	yes	1(0.3)	8(2.8)	50(17.2)	76(26.2)	155(53.4)	179(61.7)	111(38.3)
Dyslipidaemia*	no	21(5.4)	56(14.5)	115(29.7)	78(20.2)	117(30.2)	221(57.1)	166(42.9)
	yes	0(0)	3(1.9)	30(19.1)	48(30.6)	76(48.4)	101(64.3)	56(35.7)
Diabetes*	yes	1(0.8)	5(3.9)	18(14)	37(28.7)	68(52.7)	87(67.4)	42(32.6)

* all p-values either vs age or gender were <0.001

395

396

397

398

399

400

401

402

403

404

405

406

407 **FIGURE TITLES AND LEGENDS**

408 **Figure 1.**

409 **TITLE.** Severity related changes of laboratory parameters by age

410 **LEGEND.** Pearson's Chi Squared p-values. Abbreviations: CRP, C-reactive protein; LDH, lactate dehydrogenase, NK,

411 Natural Killers. IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M.

412 **Figure 2.**

413 **TITLE.** Severity related changes of laboratory parameters by gender

414 **LEGEND.** Pearson's Chi Squared p-values Abbreviations: CRP, C-reactive protein; LDH, lactate dehydrogenase, NK,

415 Natural Killers. IgG, immunoglobulin G; IgA, immunoglobulin A; IgM, immunoglobulin M.

416 **Figure 3.**

417 **TITLE.** Severity factor interactions

418 **LEGEND.** Pearson's Chi Squared p-values

419

420

421

422

423



424

425

426

427

428

429

430

431

Figure 2.




Figure 3.

